3SBio Inc. (1530.HK)
- Previous Close
5.830 - Open
5.800 - Bid 6.040 x --
- Ask 6.050 x --
- Day's Range
5.700 - 6.130 - 52 Week Range
4.910 - 8.100 - Volume
14,719,659 - Avg. Volume
17,618,070 - Market Cap (intraday)
14.755B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
9.03 - EPS (TTM)
0.670 - Earnings Date Mar 20, 2024
- Forward Dividend & Yield 0.25 (4.29%)
- Ex-Dividend Date Jul 22, 2024
- 1y Target Est
7.63
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation. In addition, the company provides TPO-105 Pediatric ITP; SSS12 Cinacalcet hydrochloride; SSS13 Sevelamer carbonate; 301S TNFR-Fc protein; AP506 Apremilast; SSS32 Tofacitinib; and MN709 Minoxidil Foam. Further, the company provides trading, project management and consultation, technology, sports, financial, investment advisory, and agricultural services. It has collaboration agreements with companies, such as Toray Industries Inc, and Toray. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
www.3sbio.comRecent News: 1530.HK
Performance Overview: 1530.HK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1530.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1530.HK
Valuation Measures
Market Cap
14.22B
Enterprise Value
12.97B
Trailing P/E
8.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.68
Price/Book (mrq)
0.94
Enterprise Value/Revenue
1.66
Enterprise Value/EBITDA
5.92
Financial Highlights
Profitability and Income Statement
Profit Margin
19.82%
Return on Assets (ttm)
6.43%
Return on Equity (ttm)
9.94%
Revenue (ttm)
7.82B
Net Income Avi to Common (ttm)
1.55B
Diluted EPS (ttm)
0.670
Balance Sheet and Cash Flow
Total Cash (mrq)
5.99B
Total Debt/Equity (mrq)
29.30%
Levered Free Cash Flow (ttm)
--
Research Analysis: 1530.HK
Company Insights: 1530.HK
1530.HK does not have Company Insights